- Receives approval from Health Canada for V-Laser as a laser system suitable for both surgical and aesthetic procedures across all skin types
- Positions V-Laser as a differentiated solution in the diverse North American market with its design optimized for all skin types
- Plans to cultivate North America as a key next-generation growth driver through physician collaboration and the development of a broad product portfolio
(February 26, 2026) WONTECH Co., Ltd. (KOSDAQ: 336570), a laser and energy-based medical solutions company led by CEOs Kim Jong-won and Kim Jung-hyun, has obtained regulatory approval in Canada for its V-Laser device, marking a significant step in accelerating its expansion into the North American market.
Health Canada approved V-Laser as a medical device designed for use across all skin types in dermatology, general surgery, and plastic surgery for both surgical and aesthetic procedures. Utilizing dual wavelengths of 1064 nm and 532 nm, the system is engineered to precisely target vascular and pigmented lesions and has been recognized as suitable for all skin types.
With this approval, V-Laser has been officially recognized as a medical device applicable for a wide range of vascular and aesthetic indications, including telangiectasia, cherry angiomas, dark circles, freckles, erythema, lentigines, hyperpigmentation, warts, skin tightening, and hair removal. WONTECH plans to leverage this certification to strengthen its local distribution network and accelerate market adoption.
North America represents the largest regional market in the global aesthetic medical laser industry in terms of revenue. According to Fortune Business Insights (2024), the market is projected to grow at a compound annual growth rate of over 10% through 2030. As a premium market where clinical reliability and the ability to address diverse indications are key factors in equipment selection, V-Laser—designed for all skin types—is expected to demonstrate strong competitiveness in the region’s ethnically diverse patient population.
Beyond a regulatory milestone, the Canadian approval represents a strategic step in expanding WONTECH’s foothold in the North American market. Following Oligio and Lavieen, the addition of V-Laser further strengthens the company’s local product portfolio. WONTECH plans to expand partnerships, accumulate clinical data, and enhance education programs to gradually build a strong physician network and broaden its North American business foundation.
A WONTECH official stated, “This V-Laser certification marks the fifth regulatory approval obtained in Canada, demonstrating the company’s continued, systematic expansion in the North American market.” The official added, “By strengthening collaboration with local physicians and building a comprehensive product portfolio aligned with market needs, we aim to position North America as a key next-generation growth driver for our global business.”
- Positions V-Laser as a differentiated solution in the diverse North American market with its design optimized for all skin types
- Plans to cultivate North America as a key next-generation growth driver through physician collaboration and the development of a broad product portfolio
▲ V-Laser Product Image
(February 26, 2026) WONTECH Co., Ltd. (KOSDAQ: 336570), a laser and energy-based medical solutions company led by CEOs Kim Jong-won and Kim Jung-hyun, has obtained regulatory approval in Canada for its V-Laser device, marking a significant step in accelerating its expansion into the North American market.
Health Canada approved V-Laser as a medical device designed for use across all skin types in dermatology, general surgery, and plastic surgery for both surgical and aesthetic procedures. Utilizing dual wavelengths of 1064 nm and 532 nm, the system is engineered to precisely target vascular and pigmented lesions and has been recognized as suitable for all skin types.
With this approval, V-Laser has been officially recognized as a medical device applicable for a wide range of vascular and aesthetic indications, including telangiectasia, cherry angiomas, dark circles, freckles, erythema, lentigines, hyperpigmentation, warts, skin tightening, and hair removal. WONTECH plans to leverage this certification to strengthen its local distribution network and accelerate market adoption.
North America represents the largest regional market in the global aesthetic medical laser industry in terms of revenue. According to Fortune Business Insights (2024), the market is projected to grow at a compound annual growth rate of over 10% through 2030. As a premium market where clinical reliability and the ability to address diverse indications are key factors in equipment selection, V-Laser—designed for all skin types—is expected to demonstrate strong competitiveness in the region’s ethnically diverse patient population.
Beyond a regulatory milestone, the Canadian approval represents a strategic step in expanding WONTECH’s foothold in the North American market. Following Oligio and Lavieen, the addition of V-Laser further strengthens the company’s local product portfolio. WONTECH plans to expand partnerships, accumulate clinical data, and enhance education programs to gradually build a strong physician network and broaden its North American business foundation.
A WONTECH official stated, “This V-Laser certification marks the fifth regulatory approval obtained in Canada, demonstrating the company’s continued, systematic expansion in the North American market.” The official added, “By strengthening collaboration with local physicians and building a comprehensive product portfolio aligned with market needs, we aim to position North America as a key next-generation growth driver for our global business.”